Sebastian Wolf
Published: Wednesday, November 1, 2017
NEW CATETHER PROVIDES SAFE AND EFFECTIVE RETINAL FLUID DRAINAGE
External drainage of subretinal fluid (SRF) using a 24-G Optiva IV catheter is safe, efficient and useful in eyes with bullous exudative retinal detachment (RD), new research suggests. In a study involving 13 eyes of 13 patients with bullous exudative RD, SRF drainage was successfully accomplished in all eyes using a transconjunctival scleral incision with the 24-G catheter. Except for one case of localised subretinal haemorrhage, no complications were noted. J Peng et al, “A Modified Technique for the Transconjunctival and Sutureless External Drainage of Subretinal Fluid in Bullous Exudative Retinal Detachment Using a 24-G i.v. Catheter”, Ophthalmologica 2017, Volume 238, Issue 4.
THREE-INJECTION LOADING DOSE EXTENDS TREATMENT-FREE INTERVAL
In a study involving 61 eyes of 56 patients with myopic choroidal neovascularisation, eyes on a pro re nata (PRN) ranibizumab regimen appeared to achieve about the same visual outcomes whether they received a loading dose of three consecutive monthly injections or a loading dose of just one injection (p= 0.824). However, after a mean follow-up of 53 months, eyes that received the three-injection loading dose had a significantly longer treatment-free interval than those that received the one-injection loading dose (36.9 months vs 19.2 months; p < 0.001).
C Calvo-González et al, “Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization”, Ophthalmologica 2017, Volume 238, Issue 4.
EARLY DETECTION AND TREATMENT ACHIEVES BETTER LONG-TERM RESULTS IN NEOVASCULAR AMD
Eyes with neovascular AMD treated early in the course of their disease appear to remain responsive to anti-VEGF therapy longer than those with more advanced disease at the time treatment is initiated, according to the findings of a retrospective review study. It showed that among 67 eyes consecutively treated with more than 30 intravitreal anti-VEGF injections between 2007 and 2014, those with good final visual acuity also had better initial VA (p = 0.020) and maintained it. In contrast, patients with moderate-to-poor final VA improved significantly after the first three monthly injections, and thereafter deteriorated consistently, mostly during the third (p = 0.019) and fourth (p = 0.006) years. Patients with initially moderate-to-poor vision also had more scarring and intraretinal fluid. O.Sagiv et all, “Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections”, Ophthalmologica 2017, Volume 238, Issue 4.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Read more...
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
Read more...
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Read more...
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Read more...
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Read more...
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Read more...
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Read more...
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Read more...
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.
Read more...